Callan Family Office LLC Makes New Investment in Elanco Animal Health Incorporated (NYSE:ELAN)

Callan Family Office LLC purchased a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 36,720 shares of the company's stock, valued at approximately $445,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Commerce Bank increased its holdings in Elanco Animal Health by 2.2% in the 3rd quarter. Commerce Bank now owns 35,114 shares of the company's stock worth $516,000 after buying an additional 741 shares during the period. Arizona State Retirement System increased its stake in shares of Elanco Animal Health by 0.8% in the fourth quarter. Arizona State Retirement System now owns 143,462 shares of the company's stock worth $1,737,000 after acquiring an additional 1,166 shares during the period. MTM Investment Management LLC raised its holdings in shares of Elanco Animal Health by 9.3% during the fourth quarter. MTM Investment Management LLC now owns 14,168 shares of the company's stock worth $172,000 after purchasing an additional 1,200 shares during the last quarter. M&T Bank Corp lifted its position in Elanco Animal Health by 5.9% during the third quarter. M&T Bank Corp now owns 26,407 shares of the company's stock valued at $388,000 after purchasing an additional 1,464 shares during the period. Finally, Venturi Wealth Management LLC boosted its holdings in Elanco Animal Health by 89.9% in the third quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company's stock valued at $50,000 after purchasing an additional 1,601 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company's stock.

Remove Ads

Elanco Animal Health Price Performance

Elanco Animal Health stock traded down $0.08 during trading on Thursday, reaching $10.32. The company had a trading volume of 3,502,374 shares, compared to its average volume of 4,661,558. The firm has a market capitalization of $5.10 billion, a PE ratio of 25.79, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44. The firm's 50-day simple moving average is $11.52 and its 200 day simple moving average is $12.81. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. Elanco Animal Health Incorporated has a 1-year low of $10.03 and a 1-year high of $18.80.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same quarter last year, the business earned $0.08 EPS. The firm's revenue for the quarter was down 1.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ELAN has been the subject of a number of recent research reports. Leerink Partnrs upgraded Elanco Animal Health to a "hold" rating in a research note on Monday, December 2nd. UBS Group decreased their price target on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Barclays lowered their price objective on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Piper Sandler decreased their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research note on Thursday, March 6th. Finally, Morgan Stanley dropped their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 26th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $15.17.

Insiders Place Their Bets

In other news, Director Lawrence Erik Kurzius acquired 10,000 shares of the firm's stock in a transaction on Tuesday, March 11th. The shares were bought at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the acquisition, the director now owns 111,459 shares of the company's stock, valued at approximately $1,136,881.80. This trade represents a 9.86 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 0.57% of the stock is owned by company insiders.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.